Please visit our MS learning channel on Youtube, which provides hundreds of topics from our education programs, that were video-recorded and archived here: -- Be empowered with MS news by registering with us:

joomla ecommerce template -- Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Thursday, September 21, 2017

IT’S RELEASE DAY FOR KINKY BRIEFS, THRICE! A Collection of short stories dedicated to MS warriors

For immediate release:  September 8, 2017
For more information, contact:

Collection of short stories dedicated to MS warriors  

MILWAUKEE, WIKinky Briefs, Thrice, the third collection of sizzling short stories by former lawyer Seelie Kay, and released today by eXtasy Books, is not only dedicated to MS warriors, it also features a story about a lawyer newly diagnosed with Multiple Sclerosis.

            Kays says it’s her favorite story in Kinky Briefs, Thrice. “Munk is a character near and dear to my heart, not only because we both suffer from MS, but because she chooses to confront the illness from a position of strength,” Kay said.  “Instead of giving up after her diagnosis, Munk seeks ways to adjust to her new limitations to ensure that she does not sacrifice her own hopes and dreams.  And one of those dreams is a healthy and lasting relationship—love.”

            Kay said when confronted with a chronic illness, you begin to question everything in your life, including your relationships. “You honestly don’t know who will stay in your life and who will flee,” she said. “The fear is that you will wind up isolated and alone.  I wanted to write this particular story to reflect what I perceive to be the right way to interact with someone who has been newly-diagnosed with a disability. ”

            She dedicates the book, “To my fellow MS Warriors: For continuing to aggressively battle against a cruel and sometimes devastating disease, as a patient, advocate, volunteer, caregiver, family member, and/or medical professional.”  Kay says many people play a positive role in the life of someone who suffers from MS, and she wanted to thank them for their efforts.

            “Because MS affects everyone differently, the search for a cure has been arduous,” Kay said.  “But I have faith that working together, we will find a cure.          

            The third book in the Kinky Briefs series continues the theme of kinky beginnings, happy endings, and sizzling encounters with lawyers in love. “From a randy AG who uses his cycle to woo a young law firm associate to a Sheikh and lawyer in a fight for their lives, or a kinky lawyer struggling to adapt to a diagnosis of a crippling, chronic illness and a rowdy fantasy about a new sheriff in town, each lawyer attacks life with humor and passion, always ready to embrace just a dash of kink,” says Kay. “You’ll laugh, you’ll cry, you might even blush, but one thing’s for certain, when you’re done reading, you’ll run out and buy a set of handcuffs!”      

            Other stories include a cowboy with PTSD, a private investigator/paralegal who gets in involved with a Hollywood action hero, and two attorneys trying to find a work-life balance in their lives after they  become new parents.  “I bring back some characters from previous books, such as the lawyer who ran off with the circus in Kinky Briefs, as well as the Sheikh and international law attorney from Wisconsin, whose relationship began in Kinky Briefs and continued in Kinky Briefs, Too,”  Kay said.  “In addition, The Garage Dweller returns, this time with disastrous results.”

            The book ends with “a story of love redeemed—a couple who found love early in life, lost it, and finally reclaim it,” she added. “I love happy endings.”

            Kinky Briefs, Thrice, published by eXtasy Books, is currently available on their website (  It will also be sold by other major booksellers, including Barnes & Noble, and  It will be available primarily as an ebook, but will also be sold in paperback by select booksellers, Kay says.
For more information, visit or follow Kay on Twitter or Facebook.
            Kay is also an MS warrior:  She writes, despite MS.

# # #

Tuesday, September 19, 2017

Study Highlights Promise, Questions in Quest for Stem Cell-based MS Treatments

AUGUST 24, 2017
Jared Kaltwasser

A promising report from India appears to bolster the case that stem cell therapies might one day reverse the progression of multiple sclerosis (MS), but experts say there remain many more questions than answers when it comes to the potential treatment option.

Earlier this month, Indian research firm Advancells announced the results of a single-patient pilot study. The firm said they used an autologous adult stem cell therapy to successfully reverse MS symptoms in a patient from New Zealand.

The patient said he was able to regain the ability to climb stairs following the procedure, something he hadn’t done in five years. The company says they plan to track MRI scans and other data over the next several months in order to understand and document the full impact of the treatment on the disease.

Despite the apparent improvement in symptoms for the Advancells patient, researchers say there’s still much not know about stem cell-based therapies.

Bruce Bebo (pictured), PhD, the executive vice president of research at the National Multiple Sclerosis Society, said it’s far too early to be able to draw any concrete conclusions about the promise of stem cell treatments for MS.

“There’s a lot of unanswered questions that need to be answered in a rigorous methodical way in order for us to really understand the full potential and all the risks,” Bebo said.

Among the questions, according to Bebo: what are the best sources for cells, what’s the best delivery method for cells, how many cells need to be transplanted, and which candidates are most likely to benefit from such a treatment?

Advancells took cells from the patient’s bone marrow, isolated adult stem cells, and then injected them back into the body at strategic points to induce natural repairs mechanisms in the body to act.

In addition to the method used by Advancells, other researchers are working on a therapy known as autologous hematopoietic stem cell transplantation, in which stem cells are withdrawn from a patient and then chemotherapy is used to weaken the patient’s immune system. Once the immune system is weakened, the stimulated stem cells are transplanted back into the patient in hopes of essentially “rebooting” the patient’s immune system so it will no longer attack the central nervous system.

One other method being studied involves growing or reprogramming cells to induce myelin repair. The National MS Society published a paper last month outlining the status of various stem cell research.

The bottom line is that, in the case of all of these methods, there have yet to be any rigorous large-scale human-based studies to demonstrate or refute the therapies.

Bebo also noted that while stem cells have been used successfully to treat macular degeneration, studies attempting to use cell-based therapies to treat Alzheimer’s and Parkinson’s diseases have proven less successful.

“There’s promise but a lot of work that needs to be done in order to fully understand both the promise and pitfalls of this approach,” Bebo said.

continue reading

MS Views and News is MAKING an IMPACT for those, affected by Multiple Sclerosis
MS Views and News provides beneficial Multiple Sclerosis education, information, resources and services. 

Iron Intake Could Contribute to Pediatric Multiple Sclerosis

SEPTEMBER 07, 2017
Rachel Lutz

A significant intake of iron may contribute to multiple sclerosis (MS) in children, according to a new report.

Researchers from the University of California, San Francisco examined 312 pediatric MS patients and 456 controls in order to to determine the association between dietary factors and MS in the population. The children were recruited from 16 US centers, and were diagnosed with MS before reaching 18 years old.

The patients and their parents also completed the Block Kids Food Screener questionnaire 2011-2016. The 41-question survey asked about development, environmental exposures, medical history, demographic information, and race.

There are anecdotal reports of amelioration of MS symptoms when a patient adopts a “healthy” diet such as Mediterranean or low-fat/ high fiber, researchers wrote. However, there are currently no dietary guidelines for patients with MS and their at-risk relatives. And so far, dietary studies for MS patients have centered on vitamin D and obesity, but not overall diets.

The researchers observed an average dietary intake of fiber, iron, and dairy was significantly lower in MS patients compared to controls. When the investigators categorized their data by males vs. females, the only average dietary difference was dietary fiber in males.

The mean calorie intake for cases and controls was similar between the groups, and the percentage energy intake from protein, carbohydrates, and fat did not present and differences between MS patients and controls.

However, the data did suggest a presence of lower iron intake among cases of pediatric MS, Dr. Julia Pakpoor told MD Magazine. The study is the first of its kind to examine the diets of pediatric MS patients, researchers wrote, while other studies looked at dietary factors in MS patients, such as fat intake, or fruit and vegetable intake, and gut microbiota modulation. 

Continue Reading

MS Views and News is MAKING an IMPACT for those, affected by Multiple Sclerosis
MS Views and News provides beneficial Multiple Sclerosis education, information, resources and services. 

How to Meditate for Beginners - 30 Tips, Tricks and Tools

Meditation is the simplest thing ... and that’s why it can be so difficult.
The following meditation tips will help you to avoid some common pitfalls beginners face, and build a strong foundation for your practice.
When you are ready to start, we offer a number free online guided meditations.
Don’t have time to read it all in one go?
Get a FREE Meditation for Beginners E-Course and follow along to a series of daily emails and videos with guided meditations, tips and tools.

Before You Meditate

Attempting to jump straight from a busy work day into a silent peaceful state of deep rest is a bit overly optimistic.
Instead, by taking a little time to prepare for your meditation you can give yourself the gift of a deeper and more pleasant experience.

Airplane mode

Possibly the most important meditation ritual of our time - put your phone on airplane mode. There’s no better way to ruin a meditation than by leaving your phone on and getting a call or text in the middle. So turn off your phone or put it on airplane mode as soon as you get ready to meditate. Still have a corded phone? Unplug it!

Warm-up your body with yoga or light exercise

Before starting your meditation do a few warm-ups or beginner’s yoga exercises. These will help to improve circulation, remove any inertia or restlessness, and will make your body feel lighter. At the least, take a walk around your building or office.
A short warm-up before meditation will also allow you to sit peacefully for a longer period time.

Calm the mind with breathing exercises

You can also do a few rounds of a yoga breathing exercise, such as Nadi Shodhan pranayama as well. Learning a simple breathing exercise like this can make meditation significantly easier.
Why, you ask? Because the breath is so connected to our mind and emotions, as soon as you slow and steady the rhythm of your breath, it quickly leads the mind into a peaceful, meditative state.


Continue reading by clicking here, to read from the source

MS Views and News is MAKING an IMPACT for those, affected by Multiple Sclerosis
MS Views and News provides beneficial Multiple Sclerosis education, information, resources and services. 

Friday, September 15, 2017

Early MS Treatment Strategies and Empowering your Body to Stay Active - in Dallas Texas


MS Views and News is MAKING an IMPACT for those, affected by Multiple Sclerosis
MS Views and News provides beneficial Multiple Sclerosis education, information, resources and services. 

Living Beyond MS - ROUND TABLE Discussion - in Monroeville, PA



Thursday, September 14, 2017

Biotech Firm Gets $688K to Build In Vitro Blood-Brain Barrier

Biotech Firm Gets $688K to Build In Vitro Blood-Brain Barrier
SEPTEMBER 13, 2017
Jared Kaltwasser

Parvivo SystemA Seattle-based biotechnology company has received a new round of federal funding that will allow it to develop an in vitro testing system that mimics the human blood-brain barrier.

Nortis Inc. was awarded a $688,000 grant from the National Institutes of Health. The money will fund the third year of a Small Business Innovation Research fast-track grant from the National Institute of Neurological Disorders and Stroke.

Nortis has developed a proprietary 3D organ modeling system called ParVivo, which regulates the biological structure of human organs to allow accurate in vitro testing. The creation of a blood-brain barrier in vitro model could have a major impact on how drug companies test and develop treatments for neurological disorders like multiple sclerosis (MS).

Kevin Banks, PhD, Nortis’ vice president of sales and marketing, told MD Magazine that the technology dovetails nicely with efforts by drug developers to reduce animal testing and lower the rate of clinical trial failures. Banks noted that about 4 of every 10 Phase III studies are failures, a ratio that translates to expensive losses for drug companies.

“This is primarily due to efficacy and safety failures of the drugs, which have been primarily tested to that point using animal models and not human models,” Banks said. “The vision of using human 3D tissue models is to reduce clinical trial failure rates by using more relevant human models early in the drug development process.”

Drug delivery to the brain has long been a challenge for pharmaceutical companies. The blood-brain barrier, which is composed of endothelial tissue, protects the brain from foreign substances and helps maintain a constant environment, but the barrier also can stop drug molecules from getting into the brain.

Thus, companies developing drugs that require entry into the brain to trigger the desired pharmacological response have a major interest in efficiently and reliably figuring out how their therapies hold up against the barrier.

Continue Reading

MS Views and News is MAKING an IMPACT for those, affected by Multiple Sclerosis
MS Views and News provides beneficial Multiple Sclerosis education, information, resources and services. 

A randomized trial of clitoral vacuum suction versus vibratory stimulation in neurogenic female orgasmic dysfunction.


Alexander M, et al. Arch Phys Med Rehabil. 2017.


OBJECTIVE: To examine safety and efficacy of use of a clitoral vacuum suction device (CVSD) versus vibratory stimulation (V) to treat orgasmic dysfunction in women with MS or SCI.
DESIGN: Randomized clinical trial.
SETTING: Two academic medical centers.
PARTICIPANTS: Thirty-one women including 20 with MS and 11 with SCI.
INTERVENTION: A 12-week trial of the use of a CVSD versus V MAIN OUTCOME MEASURES: Female Sexual Function Inventory (FSFI) and Female Sexual Distress Scale (FSDS).
RESULTS: 23 women (18 MS; 5 SCI) completed the study including 13/16 randomized to CVSD and 10/15 randomized to V. There was a statistically significant increase in total FSFI score (p=.011), desire (p=. 009), arousal (p=.009), lubrication (p=.008), orgasm (p=.012), and satisfaction (p=.049) and a significant decrease in distress as measured by FSDS (p=.020) in subjects using the CVSD. In subjects who used V, there was a statistically significant increase in the orgasm subscale of the FSFI (p=.028). Subjects using the CVSD maintained improvements 4 weeks after treatment.
CONCLUSION: CVSD is safe and overall efficacious to treat female neurogenic sexual dysfunction related to MS and SCI. V is also safe and efficacious to female neurogenic orgasmic dysfunction; however, results were limited to the active treatment period. Due to ease of access and cost, clinicians can consider use of V for women with MS or SCI with orgasmic dysfunction. CVSD is recommended for women with multiple sexual dysfunctions or for whom V is ineffective.
Copyright © 2017 American Congress of Rehabilitation Medicine. Published by Elsevier Inc. All rights reserved.


 28899827 [PubMed - as supplied by publisher]

Full text


MS Views and News is MAKING an IMPACT for those, affected by Multiple Sclerosis
MS Views and News provides beneficial Multiple Sclerosis education, information, resources and services. 

Cognitive functioning following one-year Natalizumab treatment: A non-randomized clinical trial.

Rorsman I, et al. Acta Neurol Scand. 2017.


OBJECTIVES: Cognitive impairment is common in multiple sclerosis (MS) and can have serious impact on social and occupational functioning. Natalizumab reduces relapse rates, magnetic resonance imaging (MRI) lesions, and progression of disability. Previous studies on cognitive functioning have not based inclusion on cognitive performance criteria. The aim of the present study was to determine any potential natalizumab-related cognitive effects on MS patients performing below normal limits on neuropsychological testing.
MATERIALS AND METHODS: Patients starting natalizumab (n = 21) and a quasi-control group of stable MS patients (n = 13) on first line disease modifying treatment were included following neuropsychological assessment demonstrating subnormal cognitive performance. Assessment, using ten cognitive variables, was repeated after 12 months. Symptoms of fatigue, anxiety and depression were also examined. Raw scores on the cognitive tests were transformed into Z-scores based on published age-corrected normative data.
RESULTS: Between-group analyses on difference Z-scores (baseline - follow-up) yielded significant results on Paced Auditory Serial Addition Test-2 (PASAT-2) (P = .008), with the natalizumab group showing larger improvement than quasi control patients. On PASAT-2, 28,5% from the natalizumab group demonstrated >1 SD improvement, indicative of clinically meaningful change, compared with none in the quasi control group. Patients receiving natalizumab showed within-group improvements on six of the ten cognitive variables. There were no group differences in symptoms of fatigue, anxiety or depression.
CONCLUSIONS: The results demonstrate improvement in information processing speed following 12-months of natalizumab treatment. The results are interpreted as reflection of anti-inflammatory properties of natalizumab rather than retest- or long-term restorative effects.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.


 28901547 [PubMed - as supplied by publisher]

Full text

MS Views and News is MAKING an IMPACT for those, affected by Multiple Sclerosis
MS Views and News provides beneficial Multiple Sclerosis education, information, resources and services. 

'Timed up and go' and brain atrophy: a preliminary MRI study to assess functional mobility performance in multiple sclerosis.

Lorefice L, et al. J Neurol. 2017.


Motor and cognitive disabilities are related to brain atrophy in multiple sclerosis (MS). 'Timed up and go' (TUG) has been recently tested in MS as functional mobility test, as it is able to evaluate ambulation/coordination-related tasks, as well as cognitive function related to mobility. The objective of this study is to evaluate the relationship between brain volumes and TUG performances. Inclusion criteria were a diagnosis of MS and the ability to walk at least 20 m. TUG was performed using a wearable inertial sensor. Times and velocities of TUG sub-phases were calculated by processing trunk acceleration data. 
Patients underwent to a brain MRI, and volumes of whole brain, white matter (WM), grey matter (GM), and cortical GM (C) were estimated with SIENAX. Sixty patients were enrolled. Mean age was 41.5 ± 11.6 years and mean EDSS 2.3 ± 1.2. Total TUG duration was correlated to lower WM (ρ = 0.358, p = 0.005) and GM (ρ = 0.309, p = 0.017) volumes. 
A stronger association with lower GM volume was observed for intermediate (ρ = 0.427, p = 0.001) and final turning (ρ = 0.390, p = 0.002). TUG is a useful tool in a clinical setting as it can not only evaluate patients' disability in terms of impaired functional mobility, but also estimate pathological features, such as grey atrophy.


 28894919 [PubMed - as supplied by publisher]

Full text

MS Views and News is MAKING an IMPACT for those, affected by Multiple Sclerosis
MS Views and News provides beneficial Multiple Sclerosis education, information, resources and services.